Steven Staben, Chief Scientific Officer and 10% owner of Lycia Therapeutics, Inc., filed a Form 4 on October 26, 2026, disclosing the acquisition of a stock option covering 110,896 shares of common stock with a transaction date of August 11, 2026.

Key Highlights

  • Reporting person: Steven Staben, identified in the filing as Chief Scientific Officer and a 10% owner of Lycia Therapeutics, Inc.
  • Option grant: 110,896 stock options (Right to Buy) acquired on August 11, 2026, at an exercise price of $3.70 per share.
  • Pre-IPO transaction: According to the filing, the transaction occurred prior to the issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the issuer's initial public offering, and is reported pursuant to Rule 16a-2(a).
  • Vesting schedule: The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026, subject to the reporting person's continued service.
  • Expiration date: The options expire on August 10, 2036.
  • Post-transaction holdings: Following the reported transaction, Staben beneficially owns 110,896 derivative securities directly, at a price of $0 for the derivative security itself.

Lycia Therapeutics CSO Steven Staben Discloses Pre-IPO Stock Option Award

According to the Form 4 filed with the U.S. Securities and Exchange Commission on October 26, 2026, Steven Staben, who serves as Chief Scientific Officer of Lycia Therapeutics, Inc. (NASDAQ:LYCA) and is identified as a 10% owner, received a grant of stock options covering 110,896 shares of common stock. The transaction date is listed as August 11, 2026, with no deemed execution date noted.

The filing reports the transaction in Table II, covering derivative securities. The option carries an exercise price of $3.70 per share and an expiration date of August 10, 2036. The filing states that "the transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a)." The transaction code is listed as "A," indicating acquisition.

As described in the filing's explanation of responses, the options vest as to 1/48 of the total award monthly over four years, with the first tranche having vested on September 6, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Following the reported transaction, Staben directly holds 110,896 derivative securities. The Form 4 was signed by Amy Bachrodt as Attorney-in-Fact on October 26, 2026. No non-derivative securities transactions were reported in Table I.

What Was Disclosed

This Form 4 discloses Steven Staben's acquisition of 110,896 stock options in Lycia Therapeutics, Inc. at an exercise price of $3.70, granted on August 11, 2026, prior to the company's IPO, and filed on October 26, 2026.